- Home
- SGLY vs WINT Comparison
SGLY vs WINT Comparison
Compare SGLY & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- WINT
- Stock Information
- Founded
- SGLY 2001
- WINT 1992
- Country
- SGLY United States
- WINT United States
- Employees
- SGLY N/A
- WINT N/A
- Industry
- SGLY
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGLY
- WINT Health Care
- Exchange
- SGLY Nasdaq
- WINT Nasdaq
- Market Cap
- SGLY 6.2M
- WINT 5.3M
- IPO Year
- SGLY 2008
- WINT 1995
- Fundamental
- Price
- SGLY $1.52
- WINT $0.50
- Analyst Decision
- SGLY
- WINT Hold
- Analyst Count
- SGLY 0
- WINT 1
- Target Price
- SGLY N/A
- WINT $18.00
- AVG Volume (30 Days)
- SGLY 37.1K
- WINT 549.5K
- Earning Date
- SGLY 11-14-2024
- WINT 11-26-2024
- Dividend Yield
- SGLY N/A
- WINT N/A
- EPS Growth
- SGLY N/A
- WINT N/A
- EPS
- SGLY N/A
- WINT N/A
- Revenue
- SGLY $2,742,157.00
- WINT N/A
- Revenue This Year
- SGLY N/A
- WINT N/A
- Revenue Next Year
- SGLY N/A
- WINT N/A
- P/E Ratio
- SGLY N/A
- WINT N/A
- Revenue Growth
- SGLY N/A
- WINT N/A
- 52 Week Low
- SGLY $1.27
- WINT $0.45
- 52 Week High
- SGLY $7.65
- WINT $22.32
- Technical
- Relative Strength Index (RSI)
- SGLY 40.76
- WINT 27.72
- Support Level
- SGLY $1.61
- WINT $0.45
- Resistance Level
- SGLY $2.35
- WINT $0.64
- Average True Range (ATR)
- SGLY 0.24
- WINT 0.06
- MACD
- SGLY -0.01
- WINT 0.07
- Stochastic Oscillator
- SGLY 9.57
- WINT 19.50
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.